Skip to content
Logo
  • Home
  • FeNO
    • What is FeNO?
    • FeNO in asthma
    • Benefits of FeNO use
    • Measuring FeNO with the NObreath®
  • NObreath®
    • What is the NObreath®?
    • Already own a NObreath®
    • How to use the NObreath®
    • Consumables
    • Literature
  • News
  • Medical Advisory Board
  • Software
  • Support
    • Educational Portal
    • FAQs
    • Literature
  • Contact
  • English
    • English
    • United States
Nov 27

Bedfont® Scientific Limited Expands Global Access to FeNO Testing in India

Rbeck Healthtech Private completes registration for the NObreath® FeNO device, helping to improve asthma care across the region.

Bedfont® Scientific Limited, world leaders in breath analysis, with over 48 years of experience in designing and manufacturing medical breath analysis devices, has collaborated with Rbeck Healtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more accessible in India. Rbeck Healthtech Private is an entirely diverse healthcare equipment distributor, with a portfolio specialising in pulmonology, cardiology, and rehabilitation. It has recently added the innovative NObreath® device to its offerings, expanding access to FeNO testing in India.

Asthma is a chronic lung disease which cannot be cured; however, with the correct diagnosis and treatment, people with asthma can lead normal lives. India accounts for approximately 13.1% of the global asthma burden1, meaning that improving access to essential diagnostic and management tools, such as the NObreath®, is vital. The NObreath® measures FeNO levels on exhaled breath, a key indicator in type 2 airway inflammation, which is commonly found in asthma.

Jason Smith, CEO at Bedfont®, comments, “Partnering with Rbeck Healthtech and the successful registration for the NObreath® in India is a meaningful milestone in our mission to make precision asthma care accessible worldwide. India faces a significant burden of asthma, and we believe that FeNO testing can empower clinicians with clearer insights into airway inflammation, leading to more personalised and effective treatment decisions.”

With the Global Asthma Report 2022 indicating that a considerable proportion of asthmatic individuals remain underdiagnosed or untreated2 in India, it is hoped that this strategic partnership will help expand the accessibility of FeNO testing in the region, ultimately saving lives.

To find out more about the NObreath® and how it is improving asthma care worldwide, visit the website here.

References

1.Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: the Global Asthma Network study. ERJ Open Research [Internet]. 2022 May 30;8(2):00528-2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149387/

2.The Global Asthma Report 2022 [Internet]. Globalasthmareport.org. 2022 [cited 2025 Oct 8]. Available from: https://globalasthmareport.org/regions/india.php?

 

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Contact Details

Bedfont® Scientific Ltd
Station Road, Harrietsham, Maidstone
Kent, ME17 1JA, England

Tel: +44(0)1622 851122
Email: ask@bedfont.com

Products

NObreath®

Smokerlyzer®

Gastrolyzer®

ToxCO®

Medi-Gas Check

Accreditations

ISO 13485:2016

Bedfont EC REP - Emergo

Useful Links

What is FeNO?

FeNOchart™

What is the NObreath®?

Resources

FAQs

Contact Us


References



White Bedfont text logo

© 1976-2026 Bedfont® Scientific Ltd., all rights reserved | Incorporated in England and Wales under registered number: 1289798

Legal Stuff | Privacy Notice | Help Centre